NanoViricides’ Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials

LIS Technologies Bolsters its Executive Team with the Addition of 40-Year Nuclear Industry Veteran Scott Hyman as its Director of Nuclear Fuels Marketing

Oak Ridge, Tennessee--(Newsfile Corp. - October 20, 2026) - LIS Technologies Inc. ("LIST" or "the Company"), a developer of proprietary...

error: Content is protected !!